News Related to Hypertension Secondary to Hypercortisolism

Related coverage linked through entity extraction aliases.

FDA Rejects Corcept's Relacorilant Application; Securities Lawsuits Follow

Mar 01, 2026

Corcept Therapeutics received an FDA Complete Response Letter denying approval of relacorilant for hypertension secondary to hypercortisolism, triggering a 44.76% stock decline and multiple securities class actions.

FDA Issues Complete Response Letter for Corcept's Relacorilant in Hypercortisolism

Sep 11, 2025

The FDA issued a Complete Response Letter for Corcept's relacorilant as a treatment for hypertension secondary to hypercortisolism, requesting additional evidence of effectiveness despite acknowledging positive trial results.